All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

CAR T-Cell Therapies Move Ahead in Pediatric and Adult ALL

May 22nd 2024

Carrie L. Kitko, MD, discusses the current standing of cellular therapies in adult and pediatric ALL and looks toward future developments.

Dr Neelapu on Addressing CAR T-Cell Resistance in Lymphoma

May 22nd 2024

Sattva S. Neelapu, MD, discusses mechanisms of resistance to CAR T-cell therapies in lymphoma and how these areas of need may be addressed.

Addressing Research Into the Association Between Tumor Mutations and Responses in RCC

May 21st 2024

Eliezer Van Allen, MD, discusses immuno-oncology in relation to precision cancer medicine.

Navigating the Growing Landscape of JAK Inhibitors in Myelofibrosis

May 21st 2024

Ashwin Kishtagari, MD, discusses the treatment of patients with myelofibrosis following progression on ruxolitinib.

TIBs Linked With Poor Outcomes With Anti–PD-1 Therapy Plus Axitinib in Metastatic ccRCC

May 21st 2024

Tumor-infiltrating B lymphocytes were associated with worse outcomes in patients with metastatic ccRCC treated with axitinib plus anti–PD-1 therapy.

Older Adults With Aggressive Blood Cancer Are Responsive to Treatment and Show Prolonged Survival

May 21st 2024

According to a study published in Blood Neoplasia, standard-of-care treatment for acute myeloid leukemia is safe and effective for adults over 80.

Epacadostat Plus Preoperative Chemoradiation Is Feasible in Locally Advanced Rectal Cancer

May 21st 2024

Haeseong Park, MD, MPH, discusses findings from a phase 1 study of epacadostat with preoperative chemoradiation in locally advanced rectal cancer.

Inavolisib Receives FDA Breakthrough Therapy Designation for PIK3CA-Mutated, HR+/HER2– Breast Cancer

May 21st 2024

Inavolisib/palbociclib/fulvestrant was granted FDA granted breakthrough therapy designation for PIK3CA-mutated, HR-positive/HER2-negative breast cancer.

FDA Grants Orphan Drug Designation to Azeliragon for Pancreatic Cancer

May 21st 2024

The FDA has granted orphan drug designation to azeliragon as a potential therapeutic option for patients with pancreatic cancer.

FDA Updates PDUFA Date of BLA for Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors

May 21st 2024

The FDA has updated the PDUFA target action date for the BLA for subcutaneous nivolumab in advanced or metastatic solid tumors.

First-in-Class PARP1 Selective Inhibitor Saruparib Shines in Phase 1 Trial of Advanced Solid Tumors

May 21st 2024

Timothy Yap, MBBS, PhD, FRCP, discusses encouraging data seen with the first-in-class PARP1 selective inhibitor saruparib in solid tumors and how the agent is being further investigated.

Tivumecirnon Plus Pembrolizumab Displays Activity and Tolerability in HNSCC

May 20th 2024

Jameel Muzaffar, MD, discusses findings from the phase 2 portion of the FLX475-02 study examining tivumecirnon plus pembrolizumab in HNSCC.

Adding Ibrutinib to Chemoimmunotherapy Induction Improves FFS in Younger MCL

May 20th 2024

The addition of ibrutinib to chemoimmunotherapy induction with ASCT improved rates of failure-free survival in younger patients with mantle cell lymphoma.

Neelapu Highlights the Nuances of CAR T-Cell Therapy Administration in Lymphoma

May 20th 2024

Sattva S. Neelapu, MD, discusses the optimal processes of CAR T-cell therapy administration and the remaining unmet needs in the space.

Precision Cancer Care: Preserving Normal Tissue With Proton Therapy

May 20th 2024

Radiation therapy is a critical component of cancer care that is currently being used in approximately 50% of all patients with cancer.

Mirvetuximab Soravtansine Plus Pembrolizumab Generates Reponses in pMMR FRα+ Serous Endometrial Cancer

May 20th 2024

Rebecca Porter, MD, PhD, discusses mirvetuximab soravtansine plus pembrolizumab in serous endometrial cancer and future directions for ADCs in the space.

WU-CART-007 Receives FDA RMAT and EMA PRIME Designations for R/R T-ALL and T-LBL

May 20th 2024

WU-CART-007 has received RMAT and PRIME designations in relapsed/refractory T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma.

Kara Stromberg Receives Keystone Award From Pennsylvania Academy of Nutrition and Dietetics

May 20th 2024

Kara Stromberg, MS, RD, LDN, CDCES, was recognized by the Pennsylvania Academy of Nutrition and Dietetics as a Keystone Award winner.

BTK Inhibitor Combinations Move to Forefront of CLL Investigations, Conversations

May 20th 2024

Mazyar Shadman, MD, MPH, details the efficacy of BTK inhibitors in the frontline treatment of CLL as well as safety considerations in the relapsed/refractory setting.

FDA Withdraws Accelerated Approval of Infigratinib for Advanced FGFR2+ Cholangiocarcinoma

May 20th 2024

The FDA has withdrawn the approval of infigratinib for previously treated, FGFR2-positive, advanced cholangiocarcinoma.